There are dozens of clinical trials for new medicines for mCRPC. If you've browsed clinicaltrials.gov for your area and didn't find any, I wouldn't know of any beyond that. You can ask at your local tertiary care centers if they have any.
The problem with "revisiting" is resistance and cross resistance. Medicines that attack the cancer exert selective pressure on it to evolve. It evolves a way to survive in spite of the medicine, and in so doing, often makes other medicines of that same class less effective. So Zytiga doesn't work nearly as well after Xtandi and vice versa. However, a combination of agents
may work longer. There are lots of new hormone therapies in trials: Capesaris, Orteronel, ARN-509, Galeterone, ODM-201, VT-464, and several others. They may be more effective when coupled with growth factor inhibitors, like angiogenesis inhibitors or tyrosine kinase inhibitors. These can also be coupled with Taxotere or Jevtana.
An interesting possibility is a class of drugs called de-methylators that might be able to restore the cancer's hormone and chemo sensitivity. For more information about
this and other kinds of medicines that are already approved for other uses and may be prescribed off label,
go to this link.- Allen